Physician profile
Sarah M Howell
NPI 1467550590
$653,343.41
in general payments reported to CMS, 2019-2025
27 companies · $188K in 2025
The $188K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $32K · 2021: $45K · 2022: $86K · 2023: $124K · 2024: $133K · 2025: $188K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $358K · Travel and Lodging: $63K · Food and Beverage: $21K · Consulting Fee: $3,050 · Education: $168 · Honoraria: $8.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $357,660.50 |
| Travel and Lodging | $62,922.17 |
| Food and Beverage | $20,816.62 |
| Consulting Fee | $3,050.00 |
| Education | $168.32 |
| Honoraria | $8.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $219,954.41 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Abbvie INC. | $183,993.12 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $92,488.42 | 2019-2025 | Dupixent |
| Ucb, INC. | $62,819.67 | 2019-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $35,541.49 | 2019-2025 | Nemluvio |
| Genzyme Corporation | $34,369.69 | 2021-2025 | |
| Pfizer INC. | $4,908.26 | 2019-2025 | |
| Amgen INC. | $4,906.80 | 2019-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $3,197.95 | 2019-2024 | Siliq, Duobrii |
| Dermavant Sciences, INC. | $2,890.56 | 2023 | Vtama |
| Celgene Corporation | $2,659.41 | 2019-2020 | |
| Leo Pharma INC. | $1,466.55 | 2021-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $733.01 | 2021-2025 | Ilumya, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $723.46 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $711.92 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $442.01 | 2022-2023 | Opzelura |
| Janssen Biotech, INC. | $382.32 | 2020-2024 | Stelara, Simponi Aria, Simponi |
| Genentech USA, INC. | $251.05 | 2019-2025 | Xolair |
| Arcutis Biotherapeutics, INC. | $214.58 | 2023 | |
| Sanofi-Aventis U.S. LLC | $173.50 | 2019-2021 | |
| Dermira, INC. | $162.82 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $104.62 | 2025 | Tremfya |
| Organon LLC | $90.15 | 2025 | Vtama |
| Biofrontera INC. | $63.80 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Kyowa Kirin, INC. | $47.60 | 2022-2024 | Poteligeo |
| Stemline Therapeutics INC. | $24.74 | 2022 | |
| Aclaris Therapeutics, INC. | $21.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Howell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.